Raccah Denis
Publications :
180164
Raccah
1
harvard-cite-them-right-no-et-al
50
date
desc
year
4822
https://crmbm.univ-amu.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22Q3BVICPP%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pr%5Cu00e9au%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-13%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPr%26%23xE9%3Bau%2C%20Y.%2C%20Galie%2C%20S.%2C%20Schaepelynck%2C%20P.%2C%20Armand%2C%20M.%20and%20Raccah%2C%20D.%20%282021%29%20%26%23x201C%3BBenefits%20of%20a%20Switch%20from%20Intermittently%20Scanned%20Continuous%20Glucose%20Monitoring%20%28isCGM%29%20to%20Real-Time%20%28rt%29%20CGM%20in%20Diabetes%20Type%201%20Suboptimal%20Controlled%20Patients%20in%20Real-Life%3A%20A%20One-Year%20Prospective%20Study%20%26%23xA7%3B%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BSensors%20%28Basel%2C%20Switzerland%29%26lt%3B%5C%2Fi%26gt%3B%2C%2021%2818%29%2C%20p.%206131.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fs21186131%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fs21186131%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Benefits%20of%20a%20Switch%20from%20Intermittently%20Scanned%20Continuous%20Glucose%20Monitoring%20%28isCGM%29%20to%20Real-Time%20%28rt%29%20CGM%20in%20Diabetes%20Type%201%20Suboptimal%20Controlled%20Patients%20in%20Real-Life%3A%20A%20One-Year%20Prospective%20Study%20%5Cu00a7%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannis%22%2C%22lastName%22%3A%22Pr%5Cu00e9au%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Galie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Schaepelynck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Armand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Raccah%22%7D%5D%2C%22abstractNote%22%3A%22The%20switch%20from%20intermittently%20scanned%20continuous%20glucose%20monitoring%20%28isCGM%29%20to%20real-time%20%28rt%29%20CGM%20could%20improve%20glycemic%20management%20in%20suboptimal%20controlled%20type%201%20diabetes%20patients%2C%20but%20long-term%20study%20is%20lacking.%20We%20evaluated%20retrospectively%20the%20ambulatory%20glucose%20profile%20%28AGP%29%20in%20such%20patients%20after%20switching%20from%20Free%20Style%20Libre%201%20%28FSL1%29%20to%20Dexcom%20G4%20%28DG4%29%20biosensors%20over%201%20year.%20Patients%20%28n%20%3D%2021%2C%2043%20%5Cu00b1%2015%20years%2C%20BMI%2025%20%5Cu00b1%205%2C%20HbA1c%208.1%20%5Cu00b1%201.0%25%29%20had%20severe%20hypoglycemia%20and%5C%2For%20HbA1c%20%5Cu2265%208%25.%20AGP%20metrics%20%28time-in-range%20%28TIR%29%2070-180%20mg%5C%2FdL%2C%20time-below-range%20%28TBR%29%20%26lt%3B70%20mg%5C%2FdL%20or%20%26lt%3B54%20mg%5C%2FdL%2C%20glucose%20coefficient%20of%20variation%20%28%25CV%29%2C%20time-above-range%20%28TAR%29%20%26gt%3B180%20mg%5C%2FdL%20or%20%26gt%3B250%20mg%5C%2FdL%2C%20glucose%20management%20indicator%20%28GMI%29%2C%20average%20glucose%29%20were%20collected%20the%20last%203%20months%20of%20FSL1%20use%20%28M0%29%20and%20of%20DG4%20for%203%2C%206%20%28M6%29%20and%2012%20%28M12%29%20months%20of%20use.%20Values%20were%20means%20%5Cu00b1%20standard%20deviation%20or%20medians%20%5BQ1%3BQ3%5D.%20At%20M12%20versus%20M0%2C%20the%20higher%20TIR%20%2850%20%5Cu00b1%2017%20vs.%2045%20%5Cu00b1%2016%2C%20p%20%3D%200.036%29%2C%20and%20lower%20TBR%20%26lt%3B%2070%20mg%5C%2FdL%20%282.5%20%5B1.6%3B5.5%5D%20vs.%207.0%20%5B4.5%3B12.5%5D%2C%20p%20%3D%200.0007%29%2C%20TBR%20%26lt%3B%2054%20mg%5C%2FdL%20%280.7%20%5B0.4%3B0.8%5D%20vs.%202.3%20%5B0.8%3B7.0%5D%2C%20p%20%3D%200.007%29%20and%20%25CV%20%2839%20%5Cu00b1%205%20vs.%2045%20%5Cu00b1%208%2C%20p%20%3D%200.0009%29%2C%20evidenced%20a%20long-term%20effectiveness%20of%20the%20switch.%20Compared%20to%20M6%2C%20TBR%20%26lt%3B%2070%20mg%5C%2FdL%20decreased%2C%20%25CV%20remained%20stable%2C%20while%20the%20improvement%20on%20hyperglycemia%20exposure%20decreased%20%28higher%20GMI%2C%20TAR%20and%20average%20glucose%29.%20This%20switch%20was%20a%20relevant%20therapeutic%20option%2C%20though%20a%20loss%20of%20benefit%20on%20hyperglycemia%20stressed%20the%20need%20for%20optimized%20management%20of%20threshold%20alarms.%20Nevertheless%2C%20few%20patients%20attained%20the%20recommended%20values%20for%20AGP%20metrics%2C%20and%20the%20reasons%20why%20some%20patients%20are%20%26quot%3Bresponders%26quot%3B%20vs.%20%26quot%3Bnon-responders%26quot%3B%20warrant%20to%20be%20investigated.%22%2C%22date%22%3A%222021-09-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fs21186131%22%2C%22ISSN%22%3A%221424-8220%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%224FPAP9R9%22%2C%22A4HBKZG2%22%5D%2C%22dateModified%22%3A%222025-03-19T14%3A59%3A38Z%22%7D%7D%2C%7B%22key%22%3A%225FB663YX%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pr%5Cu00e9au%20et%20al.%22%2C%22parsedDate%22%3A%222021-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPr%26%23xE9%3Bau%2C%20Y.%2C%20Armand%2C%20M.%2C%20Galie%2C%20S.%2C%20Schaepelynck%2C%20P.%20and%20Raccah%2C%20D.%20%282021%29%20%26%23x201C%3BReply%20to%20Letter%20by%20Alexander%20Seibold%20on%20%26%23x2018%3BImpact%20of%20Switching%20from%20Intermittently%20Scanned%20to%20Real-Time%20Continuous%20Glucose%20Monitoring%20Systems%20in%20a%20Type%201%20Diabetes%20Patient%20French%20Cohort%3A%20An%20Observational%20Study%20of%20Clinical%20Practices%26%23x2019%3B%20by%20Yannis%20Pr%26%23xE9%3Bau%2C%20et%20al.%20%28doi%3A%2010.1089%5C%2Fdia.2020.0674%29%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BDiabetes%20Technology%20%26amp%3B%20Therapeutics%26lt%3B%5C%2Fi%26gt%3B%2C%2023%288%29%2C%20pp.%20598%26%23x2013%3B600.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fdia.2021.0087%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fdia.2021.0087%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Reply%20to%20Letter%20by%20Alexander%20Seibold%20on%20%5C%22Impact%20of%20Switching%20from%20Intermittently%20Scanned%20to%20Real-Time%20Continuous%20Glucose%20Monitoring%20Systems%20in%20a%20Type%201%20Diabetes%20Patient%20French%20Cohort%3A%20An%20Observational%20Study%20of%20Clinical%20Practices%5C%22%20by%20Yannis%20Pr%5Cu00e9au%2C%20et%20al.%20%28doi%3A%2010.1089%5C%2Fdia.2020.0674%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannis%22%2C%22lastName%22%3A%22Pr%5Cu00e9au%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Armand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Galie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Schaepelynck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Raccah%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2Fdia.2021.0087%22%2C%22ISSN%22%3A%221557-8593%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%224FPAP9R9%22%2C%22A4HBKZG2%22%5D%2C%22dateModified%22%3A%222025-03-19T14%3A59%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22FT9AYVZA%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pr%5Cu00e9au%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPr%26%23xE9%3Bau%2C%20Y.%2C%20Armand%2C%20M.%2C%20Galie%2C%20S.%2C%20Schaepelynck%2C%20P.%20and%20Raccah%2C%20D.%20%282021%29%20%26%23x201C%3BImpact%20of%20Switching%20from%20Intermittently%20Scanned%20to%20Real-Time%20Continuous%20Glucose%20Monitoring%20Systems%20in%20a%20Type%201%20Diabetes%20Patient%20French%20Cohort%3A%20An%20Observational%20Study%20of%20Clinical%20Practices%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BDiabetes%20Technology%20%26amp%3B%20Therapeutics%26lt%3B%5C%2Fi%26gt%3B%2C%2023%284%29%2C%20pp.%20259%26%23x2013%3B267.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fdia.2020.0515%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fdia.2020.0515%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Switching%20from%20Intermittently%20Scanned%20to%20Real-Time%20Continuous%20Glucose%20Monitoring%20Systems%20in%20a%20Type%201%20Diabetes%20Patient%20French%20Cohort%3A%20An%20Observational%20Study%20of%20Clinical%20Practices%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannis%22%2C%22lastName%22%3A%22Pr%5Cu00e9au%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Armand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Galie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Schaepelynck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Raccah%22%7D%5D%2C%22abstractNote%22%3A%22Aim%3A%20Assess%20the%20impact%20of%20switching%20from%20intermittently%20scanned%20%28FreeStyle%20Libre%20%5BFSL%5D%29%20to%20real-time%20%28Dexcom%20G4%20platinum%20%5BDG4%5D%29%20continuous%20glucose%20monitoring%20systems%20on%20glycemia%20control%20in%20type%201%20diabetes%20%28T1D%29%20patients%20with%20high%20risk%20of%20hypoglycemia%20and%5C%2For%20elevated%20glycated%20hemoglobin%20%28HbA1c%29.%20Methods%3A%20We%20conducted%20an%20observational%20study%20in%2018%20T1D%20adults%20with%20poor%20glycemic%20control%20on%20FSL.%20Ambulatory%20glucose%20profile%20data%20were%20collected%20during%20the%20last%203%20months%20of%20FSL%20use%20before%20inclusion%20%28M0%20period%29%2C%20during%20the%20first%203%20months%20%28M3%20period%29%20and%20the%20last%203%20months%20%28M6%20period%29%20of%20DG4%20use.%20Data%20were%20then%20expressed%20as%2024-h%20averages.%20Biological%20HbA1c%20was%20measured%20for%20all%20three%20periods.%20Patients%20were%20their%20own-controls%20and%20statistics%20were%20performed%20using%20paired%20t-test%20or%20Wilcoxon%20for%20matched-pairs.%20Results%3A%20The%20switch%20to%20DG4%20at%20M3%20resulted%20in%20a%20higher%20time-in-range%20%28TIR%29%2070-180%5Cu2009mg%5C%2FdL%20%28median%20%5BQ1%3BQ3%5D%2C%2053.1%20%5B44.5%3B67.3%5D%20vs.%2041.5%20%5B28.5%3B62.0%5D%2C%20P%5Cu2009%3D%5Cu20090.0008%29%2C%20and%20a%20lower%20time-below-range%20%26lt%3B70%5Cu2009mg%5C%2FdL%20%28TBR%20mean%5Cu2009%5Cu00b1%5Cu2009standard%20deviation%20%28SD%29%2C%205.4%5Cu2009%5Cu00b1%5Cu20093.7%20vs.%2010.9%5Cu2009%5Cu00b1%5Cu20097.1%2C%20P%5Cu2009%3D%5Cu20090.0009%29%20and%20in%20the%20glucose%20%25%20coefficient%20of%20variation%20%28%25CV%20mean%5Cu2009%5Cu00b1%5Cu2009SD%2C%2040.1%20vs.%2046.9%2C%20P%5Cu2009%3D%5Cu20090.0001%29.%20Mean%20%28SD%29%20changes%20were%20%2B10.3%20%288.0%29%20percentage%20points%20for%20TIR%2C%20-5.5%20%285.8%29%20percentage%20points%20for%20TBR%2C%20and%20-6.8%20%285.8%29%20percentage%20points%20for%20%25CV.%20These%20results%20were%20confirmed%20at%20the%20M6%20period.%20Conclusions%3A%20Switching%20from%20FSL%20to%20DG4%20appears%20to%20provide%20a%20beneficial%20therapeutic%20option%20without%20changing%20insulin%20delivery%20systems%2C%20regardless%20of%20the%20origin%20of%20the%20patient%26%23039%3Bs%20initial%20glycemic%20issue.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1089%5C%2Fdia.2020.0515%22%2C%22ISSN%22%3A%221557-8593%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%224FPAP9R9%22%2C%22A4HBKZG2%22%5D%2C%22dateModified%22%3A%222025-03-19T14%3A59%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22F32Y9NWQ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Blonde%20et%20al.%22%2C%22parsedDate%22%3A%222020-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBlonde%2C%20L.%2C%20Berard%2C%20L.%2C%20Saremi%2C%20A.%2C%20Huang%2C%20Y.%2C%20Aroda%2C%20V.R.%20and%20Raccah%2C%20D.%20%282020%29%20%26%23x201C%3BFixed-Ratio%20Combination%20of%20Insulin%20and%20GLP-1%20RA%20in%20Patients%20with%20Longstanding%20Type%202%20Diabetes%3A%20A%20Subanalysis%20of%20LixiLan-L%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BDiabetes%20Therapy%3A%20Research%2C%20Treatment%20and%20Education%20of%20Diabetes%20and%20Related%20Disorders%26lt%3B%5C%2Fi%26gt%3B%2C%2011%284%29%2C%20pp.%201007%26%23x2013%3B1015.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs13300-020-00797-y%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs13300-020-00797-y%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fixed-Ratio%20Combination%20of%20Insulin%20and%20GLP-1%20RA%20in%20Patients%20with%20Longstanding%20Type%202%20Diabetes%3A%20A%20Subanalysis%20of%20LixiLan-L%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%22%2C%22lastName%22%3A%22Blonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lori%22%2C%22lastName%22%3A%22Berard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aramesh%22%2C%22lastName%22%3A%22Saremi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yao%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanita%20R.%22%2C%22lastName%22%3A%22Aroda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Raccah%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20With%20longer%20duration%20and%20progression%20of%20type%202%20diabetes%20%28T2D%29%2C%20%5Cu03b2-cell%20function%20deteriorates%20and%20insulin%20therapy%20often%20becomes%20necessary.%20Glucagon-like%20peptide-1%20receptor%20agonists%20such%20as%20lixisenatide%20that%20do%20not%20rely%20only%20on%20%5Cu03b2-cell%20function%20and%20glucagon%20suppression%20primarily%2C%20but%20also%20lower%20glucose%20by%20other%20%28insulin-independent%29%20mechanisms%20such%20as%20delayed%20gastric%20emptying%2C%20may%20be%20appropriate%20adjuvant%20therapy%20to%20basal%20insulin%20in%20patients%20with%20longstanding%20T2D.%5CnMETHODS%3A%20We%20assessed%20the%20efficacy%20and%20safety%20of%20insulin%20glargine%20%28iGlar%29%20versus%20iGlarLixi%2C%20a%20fixed-ratio%20combination%20of%20iGlar%20and%20lixisenatide%2C%20stratified%20by%20quartiles%20%28Q%29%20of%20T2D%20duration%20%28%5Cu2264%5Cu20097.305%20%5BQ1%5D%2C%5Cu2009%26gt%3B%5Cu20097.305%20to%20%5Cu2264%5Cu200910.75%20%5BQ2%5D%2C%5Cu2009%26gt%3B%5Cu200910.75%20to%20%5Cu2264%5Cu200915.67%20%5BQ3%5D%2C%20and%5Cu2009%26gt%3B%5Cu200915.67%5Cu00a0years%20%5BQ4%5D%29%20in%20the%20LixiLan-L%20trial%20%28N%5Cu2009%3D%5Cu2009736%29.%5CnRESULTS%3A%20Across%20all%20quartiles%2C%20the%20reduction%20in%20glycated%20haemoglobin%20was%20greater%20with%20iGlarLixi%20versus%20iGlar%2C%20and%20the%20difference%20was%20most%20pronounced%20in%20patients%20with%20the%20longest%20duration%20%28Q4%3B%20least%20squares%20mean%20difference%20%5Bstandard%20error%5D%20-%5Cu20090.62%20%5B0.13%5D%2C%20P%5Cu2009%26lt%3B%5Cu20090.0001%29.%20Additionally%2C%20hypoglycaemia%20rates%20were%20significantly%20lower%20with%20iGlarLixi%20versus%20iGlar%20in%20patients%20in%20Q4%20%283.3%20vs.%206.9%20events%5C%2Fpatient-year%2C%20P%5Cu2009%26lt%3B%5Cu20090.0001%29.%5CnCONCLUSION%3A%20iGlarLixi%20lowered%20glycated%20haemoglobin%20more%20versus%20iGlar%20regardless%20of%20T2D%20duration%2C%20with%20benefit%20retained%20even%20among%20patients%20with%20the%20longest%20T2D%20duration.%22%2C%22date%22%3A%222020-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs13300-020-00797-y%22%2C%22ISSN%22%3A%221869-6953%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22A4HBKZG2%22%2C%22TXRC8BWU%22%5D%2C%22dateModified%22%3A%222022-02-27T07%3A26%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22EQ5R8BUH%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Raccah%20et%20al.%22%2C%22parsedDate%22%3A%222019-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRaccah%2C%20D.%2C%20Guerci%2C%20B.%2C%20Ajmera%2C%20M.%2C%20Davis%2C%20K.%2C%20Meyers%2C%20J.%2C%20Lew%2C%20E.%2C%20Shaunik%2C%20A.%20and%20Blonde%2C%20L.%20%282019%29%20%26%23x201C%3BClinical%20implications%20of%20prolonged%20hyperglycaemia%20before%20basal%20insulin%20initiation%20in%20type%202%20diabetes%20patients%3A%20An%20electronic%20medical%20record%20database%20analysis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEndocrinology%2C%20Diabetes%20%26amp%3B%20Metabolism%26lt%3B%5C%2Fi%26gt%3B%2C%202%283%29%2C%20p.%20e00061.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fedm2.61%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fedm2.61%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20implications%20of%20prolonged%20hyperglycaemia%20before%20basal%20insulin%20initiation%20in%20type%202%20diabetes%20patients%3A%20An%20electronic%20medical%20record%20database%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Raccah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Guerci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mayank%22%2C%22lastName%22%3A%22Ajmera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliana%22%2C%22lastName%22%3A%22Meyers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisheva%22%2C%22lastName%22%3A%22Lew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alka%22%2C%22lastName%22%3A%22Shaunik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%22%2C%22lastName%22%3A%22Blonde%22%7D%5D%2C%22abstractNote%22%3A%22Aims%3A%20To%20assess%20the%20effect%20of%20duration%20of%20hyperglycaemia%20before%20basal%20insulin%20%28BI%29%20initiation%20on%20clinical%20outcomes%20in%20type%202%20diabetes%20%28T2D%29.%5CnMaterials%20and%20methods%3A%20Patients%20with%20T2D%20who%20initiated%20BI%20during%202009-2013%2C%20had%20continuous%20enrolment%20for%20%5Cu22652%5Cu00a0years%20preceding%20and%20%5Cu22651%5Cu00a0year%20following%20BI%20initiation%20%28%26quot%3Bindex%20date%26quot%3B%29%2C%20and%20had%20%5Cu22651%20glycated%20haemoglobin%20%28A1C%29%20measure%20not%20at%20target%20%28ie%2C%20%5Cu22657.0%25%29%20within%206%5Cu00a0months%20preindex%20date%20were%20included%20in%20the%20study.%20Patients%20were%20stratified%20by%20preindex-date%20duration%20of%20A1C%20%5Cu22657.0%25.%20Longitudinal%20A1C%2C%20weight%2C%20BMI%2C%20and%20diabetes%20medication%20were%20compared%20between%20cohorts%20for%20up%20to%2015-month%20follow-up.%5CnResults%3A%20Of%2037%5Cu00a0053%20patients%20who%20initiated%20BI%2C%2040.7%25%2C%2015.3%25%2C%2016.0%25%2C%20and%2028.0%25%2C%20respectively%2C%20had%20uncontrolled%20A1C%20for%20%26lt%3B6%2C%206-%26lt%3B12%2C%2012-%26lt%3B18%20and%2018-24%5Cu00a0months%20preindex%20date.%20Baseline%20characteristics%20were%20similar%20between%20cohorts.%20Baseline%20A1C%20values%20were%20similar%20across%20cohorts%20%289.2%25-9.6%25%29.%20Mean%20follow-up%20A1C%20values%20were%20higher%20with%20longer%20preindex-date%20duration%20of%20uncontrolled%20A1C%20%288.0%5Cu00a0%5Cu00b1%5Cu00a01.7%25%2C%208.2%5Cu00a0%5Cu00b1%5Cu00a01.6%25%2C%208.5%5Cu00a0%5Cu00b1%5Cu00a01.7%25%2C%20and%208.6%5Cu00a0%5Cu00b1%5Cu00a01.7%25%20for%20%26lt%3B6%2C%206-%26lt%3B12%2C%2012-%26lt%3B18%2C%20and%2018-24%5Cu00a0months%29%3B%20attainment%20of%20A1C%20%26lt%3B7.0%25%20worsened%20with%20increasing%20preindex-date%20duration%20of%20A1C%20%5Cu22657.0%25%20%2829.6%25%2C%2020.0%25%2C%2014.6%25%2C%20and%2011.5%25%20for%20%26lt%3B6%2C%206-%26lt%3B12%2C%2012-%26lt%3B18%2C%20and%2018-24%5Cu00a0months%29.%5CnConclusions%3A%20These%20data%20suggest%20that%20longer%20duration%20of%20uncontrolled%20A1C%20before%20BI%20initiation%20increases%20the%20risk%20of%20not%20reaching%20glycaemic%20targets.%20However%2C%20target%20attainment%20was%20poor%20in%20all%20cohorts%2C%20highlighting%20inadequate%20glycaemic%20control%20as%20an%20important%20unmet%20need%20in%20US%20patients%20with%20T2D.%22%2C%22date%22%3A%222019-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fedm2.61%22%2C%22ISSN%22%3A%222398-9238%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22A4HBKZG2%22%2C%22TXRC8BWU%22%5D%2C%22dateModified%22%3A%222022-02-27T07%3A26%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22B8VT4NQQ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Benhamou%20et%20al.%22%2C%22parsedDate%22%3A%222019-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBenhamou%2C%20P.-Y.%2C%20Franc%2C%20S.%2C%20Reznik%2C%20Y.%2C%20Thivolet%2C%20C.%2C%20Schaepelynck%2C%20P.%2C%20Renard%2C%20E.%2C%20Guerci%2C%20B.%2C%20Chaillous%2C%20L.%2C%20Lukas-Croisier%2C%20C.%2C%20Jeandidier%2C%20N.%2C%20Hanaire%2C%20H.%2C%20Borot%2C%20S.%2C%20Doron%2C%20M.%2C%20Jallon%2C%20P.%2C%20Xhaard%2C%20I.%2C%20Melki%2C%20V.%2C%20Meyer%2C%20L.%2C%20Delemer%2C%20B.%2C%20Guillouche%2C%20M.%2C%20Schoumacker-Ley%2C%20L.%2C%20Farret%2C%20A.%2C%20Raccah%2C%20D.%2C%20Lablanche%2C%20S.%2C%20Joubert%2C%20M.%2C%20Penfornis%2C%20A.%2C%20Charpentier%2C%20G.%20and%20DIABELOOP%20WP7%20Trial%20Investigators%20%282019%29%20%26%23x201C%3BClosed-loop%20insulin%20delivery%20in%20adults%20with%20type%201%20diabetes%20in%20real-life%20conditions%3A%20a%2012-week%20multicentre%2C%20open-label%20randomised%20controlled%20crossover%20trial%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Lancet.%20Digital%20Health%26lt%3B%5C%2Fi%26gt%3B%2C%201%281%29%2C%20pp.%20e17%26%23x2013%3Be25.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2589-7500%2819%2930003-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2589-7500%2819%2930003-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Closed-loop%20insulin%20delivery%20in%20adults%20with%20type%201%20diabetes%20in%20real-life%20conditions%3A%20a%2012-week%20multicentre%2C%20open-label%20randomised%20controlled%20crossover%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Benhamou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvia%22%2C%22lastName%22%3A%22Franc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Reznik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Thivolet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Schaepelynck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Renard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Guerci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucy%22%2C%22lastName%22%3A%22Chaillous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Lukas-Croisier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Jeandidier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Hanaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Borot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maeva%22%2C%22lastName%22%3A%22Doron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Jallon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilham%22%2C%22lastName%22%3A%22Xhaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Melki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Delemer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Guillouche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurene%22%2C%22lastName%22%3A%22Schoumacker-Ley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Farret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Raccah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Lablanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Joubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alfred%22%2C%22lastName%22%3A%22Penfornis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Charpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22DIABELOOP%20WP7%20Trial%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Closed-loop%20insulin%20delivery%20systems%20are%20expected%20to%20become%20a%20standard%20treatment%20for%20patients%20with%20type%201%20diabetes.%20We%20aimed%20to%20assess%20whether%20the%20Diabeloop%20Generation%201%20%28DBLG1%29%20hybrid%20closed-loop%20artificial%20pancreas%20system%20improved%20glucose%20control%20compared%20with%20sensor-assisted%20pump%20therapy.%5CnMETHODS%3A%20In%20this%20multicentre%2C%20open-label%2C%20randomised%2C%20crossover%20trial%2C%20we%20recruited%20adults%20%28aged%20%5Cu226518%20years%29%20with%20at%20least%20a%202%20year%20history%20of%20type%201%20diabetes%2C%20who%20had%20been%20treated%20with%20external%20insulin%20pump%20therapy%20for%20at%20least%206%20months%2C%20had%20glycated%20haemoglobin%20%28HbA1c%29%20of%2010%25%20or%20less%20%2886%20mmol%5C%2Fmol%29%2C%20and%20preserved%20hypoglycaemia%20awareness.%20After%20a%202-week%20run-in%20period%2C%20patients%20were%20randomly%20assigned%20%281%3A1%29%20with%20a%20web-based%20system%20in%20randomly%20permuted%20blocks%20of%20two%2C%20to%20receive%20insulin%20via%20the%20hybrid%20closed-loop%20system%20%28DBLG1%3B%20using%20a%20machine-learning-based%20algorithm%29%20or%20sensor-assisted%20pump%20therapy%20over%2012%20weeks%20of%20free%20living%2C%20followed%20by%20an%208-week%20washout%20period%20and%20then%20the%20other%20intervention%20for%2012%20weeks.%20The%20primary%20outcome%20was%20the%20proportion%20of%20time%20that%20the%20sensor%20glucose%20concentration%20was%20within%20the%20target%20range%20%283%5Cu00b79-10%5Cu00b70%20mmol%5C%2FL%29%20during%20the%2012%20week%20study%20period.%20Efficacy%20analyses%20were%20done%20in%20the%20modified%20intention-to-treat%20population%2C%20which%20included%20all%20randomly%20assigned%20patients%20who%20completed%20both%2012%20week%20treatment%20periods.%20Safety%20analyses%20were%20done%20in%20all%20patients%20who%20were%20exposed%20to%20either%20of%20the%20two%20treatments%20at%20least%20once%20during%20the%20study.%20This%20trial%20is%20registered%20with%20ClinicalTrials.gov%2C%20number%20NCT02987556.%5CnFINDINGS%3A%20Between%20March%203%2C%202017%2C%20and%20June%2019%2C%202017%2C%2071%20patients%20were%20screened%2C%20and%2068%20eligible%20patients%20were%20randomly%20assigned%20to%20the%20DBLG1%20group%20%28n%3D33%29%20or%20the%20sensor-assisted%20pump%20therapy%20group%20%28n%3D35%29%2C%20of%20whom%20five%20dropped%20out%20in%20the%20washout%20period%20%28n%3D1%20pregnancy%3B%20n%3D4%20withdrew%20consent%29.%2063%20patients%20completed%20both%2012%20week%20treatment%20periods%20and%20were%20included%20in%20the%20modified%20intention-to-treat%20analysis.%20The%20proportion%20of%20time%20that%20the%20glucose%20concentration%20was%20within%20the%20target%20range%20was%20significantly%20higher%20in%20the%20DBLG1%20group%20%2868%5Cu00b75%25%20%5BSD%209%5Cu00b74%5D%20than%20the%20sensor-assisted%20pump%20group%20%2859%5Cu00b74%25%20%5B10%5Cu00b72%5D%3B%20mean%20difference%209%5Cu00b72%25%20%5B95%25%20CI%206%5Cu00b74%20to%2011%5Cu00b79%5D%3B%20p%26lt%3B0%5Cu00b70001%29.%20Five%20severe%20hypoglycaemic%20episodes%20occurred%20in%20the%20DBLG1%20group%20and%20three%20episodes%20occurred%20in%20the%20sensor-assisted%20pump%20therapy%20group%2C%20which%20were%20associated%20with%20hardware%20malfunctions%20or%20human%20error.%5CnINTERPRETATION%3A%20The%20DBLG1%20system%20improves%20glucose%20control%20compared%20with%20sensor-assisted%20insulin%20pumps.%20This%20finding%20supports%20the%20use%20of%20closed-loop%20technology%20combined%20with%20appropriate%20health%20care%20organisation%20in%20adults%20with%20type%201%20diabetes.%5CnFUNDING%3A%20French%20Innovation%20Fund%2C%20Diabeloop.%22%2C%22date%22%3A%222019-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2589-7500%2819%2930003-2%22%2C%22ISSN%22%3A%222589-7500%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22A4HBKZG2%22%2C%22TXRC8BWU%22%5D%2C%22dateModified%22%3A%222024-11-21T08%3A39%3A28Z%22%7D%7D%5D%7D
Préau, Y., Galie, S., Schaepelynck, P., Armand, M. and Raccah, D. (2021) “Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study §,” Sensors (Basel, Switzerland), 21(18), p. 6131. Available at: https://doi.org/10.3390/s21186131.
Préau, Y., Armand, M., Galie, S., Schaepelynck, P. and Raccah, D. (2021) “Reply to Letter by Alexander Seibold on ‘Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices’ by Yannis Préau, et al. (doi: 10.1089/dia.2020.0674),” Diabetes Technology & Therapeutics, 23(8), pp. 598–600. Available at: https://doi.org/10.1089/dia.2021.0087.
Préau, Y., Armand, M., Galie, S., Schaepelynck, P. and Raccah, D. (2021) “Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices,” Diabetes Technology & Therapeutics, 23(4), pp. 259–267. Available at: https://doi.org/10.1089/dia.2020.0515.
Blonde, L., Berard, L., Saremi, A., Huang, Y., Aroda, V.R. and Raccah, D. (2020) “Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L,” Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders, 11(4), pp. 1007–1015. Available at: https://doi.org/10.1007/s13300-020-00797-y.
Raccah, D., Guerci, B., Ajmera, M., Davis, K., Meyers, J., Lew, E., Shaunik, A. and Blonde, L. (2019) “Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis,” Endocrinology, Diabetes & Metabolism, 2(3), p. e00061. Available at: https://doi.org/10.1002/edm2.61.
Benhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., Hanaire, H., Borot, S., Doron, M., Jallon, P., Xhaard, I., Melki, V., Meyer, L., Delemer, B., Guillouche, M., Schoumacker-Ley, L., Farret, A., Raccah, D., Lablanche, S., Joubert, M., Penfornis, A., Charpentier, G. and DIABELOOP WP7 Trial Investigators (2019) “Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial,” The Lancet. Digital Health, 1(1), pp. e17–e25. Available at: https://doi.org/10.1016/S2589-7500(19)30003-2.